ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER Drug Patent Profile

When do Rocephin W/ Dextrose In Plastic Container patents expire, and when can generic versions of Rocephin W/ Dextrose In Plastic Container launch?

Rocephin W/ Dextrose In Plastic Container is a drug marketed by Hoffmann La Roche and is included in one NDA.

The generic ingredient in ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER is ceftriaxone sodium. There are twenty-six drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the ceftriaxone sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rocephin W/ Dextrose In Plastic Container

A generic version of ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER was approved as ceftriaxone sodium by ANDA REPOSITORY on January 20^th, 2017.

Summary for ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hoffmann La Roche	ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER	ceftriaxone sodium	INJECTABLE;INJECTION	050624-001	Feb 11, 1987		DISCN	Yes	No
Hoffmann La Roche	ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER	ceftriaxone sodium	INJECTABLE;INJECTION	050624-002	Feb 11, 1987		DISCN	Yes	No
Hoffmann La Roche	ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER	ceftriaxone sodium	INJECTABLE;INJECTION	050624-003	Feb 11, 1987		DISCN	Yes	No

Last updated: July 17, 2026

Rocephin With Dextrose in Plastic Container (ceftriaxone): Investment Scenario and Patent/Regulatory Fundamentals

Executive summary. Rocephin With Dextrose in Plastic Container is a branded ceftriaxone combination presentation. The investment thesis is driven by (1) how fast ceftriaxone generic and authorized generic coverage expands across dosing strengths and pack formats, (2) whether any last formulation, packaging, or method-of-use patents still restrain generic entry in the US and key ex-US markets, and (3) how FDA labeling, switching from branded to generic, and hospital purchasing dynamics affect realized net price. In the US, ceftriaxone has mature generic competition in most clinically interchangeable formats; branded ROCEPHIN is typically a niche or share-protected product depending on remaining exclusivities, contract positioning, and supply continuity.

---

What patents protect Rocephin with dextrose in plastic container (ceftriaxone) across the US and Europe?

Featured snippet answer. Patent protection for ROCEPHIN is generally tied to ceftriaxone drug substance and/or early branded formulations, with later protection often shifting to specific formulation details, manufacturing controls, and packaging/administration-related claims. For “with dextrose in plastic container,” any remaining barriers tend to be narrow to the exact presentation.

Patent estate reality for ceftriaxone-branded presentations

For a mature antibiotic like ceftriaxone:

• Core composition-of-matter and early process patents have generally aged out or expired in most jurisdictions.
• Remaining value typically comes from secondary patents (formulation, stability, container/closure compatibility, and administration-related performance), plus trademark and exclusivity mechanics tied to specific listed NDA labeling.
• In practice, generic entry risk is usually high once FDA approval pathways and bioequivalence standards are met, unless a later patent blocks use of the exact listed drug’s route/dose form.

US-specific protection checkpoints

In the US, “with dextrose” presentation risks being treated as a variant of an already-available reference active (ceftriaxone) where generics can reference an approved listed drug (RLD) and offer a comparable container/pack format unless a formulation or method-of-use patent blocks filing.

Investment implication: without verifiable, still-in-force patents that specifically cover the “plastic container with dextrose” presentation as listed in the Orange Book, investors should model a “rapid generic share erosion” path and discount long-duration branded cash flows.

---

When does Rocephin (ceftriaxone) lose exclusivity and how does that affect launch timing for generics?

Featured snippet answer. For ceftriaxone branded presentations, exclusivity windows generally ended years ago. Generic entry timing is usually constrained by:

• any remaining unexpired Orange Book patents (listed for the specific NDA strength/dosage form),
• patent litigation outcomes for any barriers still in force,
• and settlement terms that define “design-around” feasibility and launch dates.

Exclusivity vs patent barriers

• Exclusivity (5-year, 3-year, or pediatric where applicable) is typically linked to initial NDA/BLA approval or supplemental approvals. Mature antibiotics rarely retain meaningful exclusivity years into the lifecycle.
• Patents are more common residual barriers. Even then, barriers can be narrow, allowing design-around filings that omit protected features.

Generic entry scenario

A realistic scenario for “with dextrose in plastic container” is:

1. Generic file-to-approval progression occurs once a Paragraph IV (or non-PIV route) is accepted for the RLD.
2. Launch is triggered after a 180-day exclusivity event (for the first filer) or at the end of the effective litigation stay/market-entry design restrictions.
3. Hospital adoption accelerates once contracting and supply reliability align.

Investment implication: the main timing variable is not clinical differentiation. It is whether any still-in-force listed patent remains enforceable against generics that want to sell the same presentation strength and container system.

---

How many Orange Book patents cover ceftriaxone “Rocephin with dextrose in plastic container” and what is their strength distribution?

Featured snippet answer. For mature single-entity antibiotics, patent lists often include a mix of early chemical/process filings (largely expired) and later secondary filings that are fewer in number and more likely to be narrow.

How investors should structure patent-strength scoring

Even without a live Orange Book pull in this environment, investors typically score:

• Count of Orange Book “active” patents by expiration date.
• Claim scope: does the claim cover the exact dextrose-in-container formulation or only broader composition/compatibility attributes?
• Litigation history: prior enforcement patterns predict how reliably courts have enforced similar claim types.
• Regulatory fit: whether a generic can craft a non-infringing container/formulation spec while still meeting labeling and performance expectations.

High-level strength distribution investors expect for mature antibiotics

• Chemical and process patents: usually expired.
• Formulation/package compatibility claims: fewer and can expire later, but are harder to assert broadly.
• Method-of-use claims: less common for antibiotic solutions unless tightly tied to specific regimens or dosing strategies that alter label.

Investment implication: the investment case hinges on narrow, presentation-specific patent barriers that can still delay generic substitution in certain procurement channels. Without those barriers, branded economics compress.

---

What patent litigation and settlement agreements have historically affected generic ceftriaxone products?

Featured snippet answer. Ceftriaxone generic launches have historically been driven by Paragraph IV challenges and litigation stays that create short-term “tempo” benefits for first filers and settlements that define design-around scopes.

Where litigation usually concentrates

• Whether the generic product design infringes formulation/container compatibility claims.
• Whether patents are invalid (obviousness, lack of enablement, or claim indefiniteness).
• Whether labeling or manufacturing process details infringe method claims.

Settlement-driven risk

Settlements can:

• permit earlier launch for non-infringing design variants,
• restrict launch to certain strengths, containers, or dosing presentations,
• or provide “pay-to-delay” style economic considerations (where enforceable within the regulatory/legal framework).

Investment implication: for ROCEPHIN-with-dextrose specific presentation, settlements, if any, can be format-specific. The relevant question for investors is whether the settlement permits generics to sell the dextrose-in-plastic container presentation or only alternate packaging formats.

---

What is the FDA Orange Book status and regulatory classification of Rocephin with dextrose in plastic container?

Featured snippet answer. As an injectable ceftriaxone product, ROCEPHIN is regulated as an approved drug with an Orange Book listing that ties specific dosage forms/strengths to patent coverage. Mature ceftriaxone products typically have many FDA-approved generics for injectable use.

Pathway and interchangeability

• Generics generally rely on bioequivalence for solution/injectable products where applicable.
• Therapeutic interchange in hospitals is largely controlled by:
  • pharmacy formularies,
  • supply chain continuity,
  • and contracting vehicles tied to WAC-to-NADAC spreads.

Investment implication: label position beats “science”

For hospital antibiotics, brand differentiation is less about incremental efficacy and more about procurement economics. Investors should treat regulatory status as a constraint on entry timing, not a driver of long-term demand.

---

What generic entry risks exist for ceftriaxone dextrose-in-container presentations in the US?

Featured snippet answer. Generic entry risk is high for mature ceftriaxone presentations unless narrow Orange Book patents specifically cover the dextrose-in-container formulation and container system, with active enforceability and non-design-around scope.

Design-around vectors generics typically use

• Different container system or packaging parameters that avoid compatibility claims.
• Different formulation ratios or excipient handling where the claim requires exact attributes.
• Different manufacturing process parameters if process-based claims exist and are enforceable.

Procurement risk

Even if a generic is not immediately approved, procurement can switch quickly once approved and competitively priced, especially for:

• high-volume inpatient use,
• infectious disease panels,
• and standard-of-care pathways where ceftriaxone is common.

Investment implication: the credible downside case is fast price compression after generic approvals for the exact listed presentation.

---

How does Rocephin with dextrose compare with other ceftriaxone products and what matters commercially?

Featured snippet answer. Commercially, ROCEPHIN’s differentiator is rarely clinical. It is availability, pack configuration, and contracting position. Therapeutic interchangeability means the competitor set is dominated by “same drug, equivalent strength, acceptable packaging form.”

Competitive landscape dimensions investors should monitor

• Strength coverage: whether competitors match the same strength presentation.
• Container system: whether the competitor uses the same plastic container type and compatible administration pathway.
• Supply continuity: stock-outs disproportionately shift demand to available suppliers.
• Pricing contracts: hospital group purchasing drives net pricing more than wholesale list prices.

Investment implication

The “with dextrose in plastic container” label exists to meet a specific administration or stability requirement. If generics can meet that requirement, price becomes the primary determinant of market share.

---

Which companies sell competing ceftriaxone injectable products and how does that change pricing leverage?

Featured snippet answer. Competing companies include generic manufacturers with approved injectable ceftriaxone offerings; pricing leverage shifts to the supplier with the best contract terms and consistent supply.

How investors should model competitor moves

• Market share shifts after first approvals and after contracting cycles.
• Subsequent entries increase competitive pressure beyond the “first filer” advantage.
• Shortages by any supplier can temporarily restore pricing power for the nearest available brand or alternate generic.

Investment implication: invest with an explicit scenario plan that includes supply disruption and contract renegotiations.

---

What revenue exposure does ROCEPHIN’s presentation-level economics create for branded investors and partners?

Featured snippet answer. Revenue exposure is presentation- and contract-specific, with the fastest compression usually occurring for standardized injectable antibiotics once multiple approved generics are available and hospital formularies normalize to the lowest-cost option.

Key revenue drivers

• Branded net price vs generic NADAC-indexed pricing.
• Share retention based on supply reliability and contract protections.
• Conversion rates for tendered inpatient purchasing.

Investment implication

Presentation-level offerings often underperform once competitors match the same container/strength. Investors should tie revenue forecasts to:

• anticipated generic share drift after approval milestones,
• and whether any remaining Orange Book patents delay exact-presentation substitution.

---

How strong is the patent estate for ceftriaxone formulations and packaging, and is it investable?

Featured snippet answer. For mature ceftriaxone, investability depends on the presence of still-in-force, narrow formulation or packaging patents tied to the exact “dextrose in plastic container” presentation and whether enforcement outcomes prevent design-around.

Patent estate strength screening criteria

Investors should treat patent estates as “actionable only if”:

• active patents exist with expiration dates meaningfully in the future,
• claim scope maps closely to the exact RLD presentation attributes,
• and litigation history indicates enforceability in similar claim types.

Investment implication

If the patent estate is mostly expired or design-aroundable, a conservative view is that branded ROCEPHIN revenue is structurally pressured and the investment case depends on near-term market access strategies, not long-duration exclusivity.

---

What regulatory and manufacturing/IP barriers delay generic substitution for injectable ceftriaxone solutions?

Featured snippet answer. Barriers are mostly procedural and legal: patent stays from Paragraph IV, litigation outcomes, and the ability to demonstrate acceptable product equivalence. Manufacturing complexity is not usually a dominant barrier for ceftriaxone injectables, but container/closure compatibility can matter.

Manufacturing and quality system constraints

• Container-closure compatibility validation.
• Stability and shelf-life for the specific formulation system.
• Sterility assurance and aseptic processing controls.

Investment implication

Even after approval, the bottleneck can be scale-up plus validation for the exact container/pack presentation. That can temporarily slow substitution in certain SKUs.

---

How would an investor model the most likely generic launch scenarios for this presentation?

Featured snippet answer. Investors typically model three cases: (1) fast generic penetration for exact presentation, (2) partial penetration with alternate containers/strengths first, and (3) delayed penetration if litigation or design-around fails.

Scenario framework

• Base case (fast exact-presentation entry): assumes no meaningful still-in-force, non-design-around patent coverage for “dextrose in plastic container.”
• Bull case (delayed exact-presentation entry): assumes active Orange Book patents exist and are enforceable, pushing entry to a later date or limiting to alternate packaging/strengths.
• Bear case (slowest substitution): assumes both litigation delays and manufacturing/compatibility barriers postpone broad availability.

Investment implication

For mature antibiotics, market share usually follows availability plus contract pricing faster than it follows legal timelines. Investors should weight procurement dynamics heavily.

---

Key Takeaways

• Branded ROCEPHIN with dextrose in plastic container faces high structural pressure from mature ceftriaxone generic ecosystems; the main determinant of branded durability is remaining, presentation-specific patent enforceability and litigation outcomes tied to exact Orange Book-listed attributes.
• Exclusivity effects are generally minimal for mature ceftriaxone; patent and Paragraph IV tempo are the practical timing drivers.
• Commercial differentiation is procurement-led: contract placement, supply reliability, and pack configuration matter more than clinical novelty.
• Investment scenarios should be built around SKU-level generic substitution speed, not broad “drug class” assumptions.

---

FAQs

1. Does the presence of dextrose in the ceftriaxone solution materially change generic approval risk versus ceftriaxone alone?
2. If a generic challenges an Orange Book patent, which outcomes most affect launch timing for specific injection strengths?
3. Can generics avoid formulation or container-compatibility claims by changing the plastic container system or excipient handling?
4. How do hospital contracting cycles typically accelerate the switch from branded ROCEPHIN to approved generics once launched?
5. What SKU-level supply or stability constraints can slow adoption even when FDA approval is obtained?

---

References (APA)

1. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. (n.d.). Drug Approval and Databases. U.S. Food and Drug Administration.
3. FDA. (n.d.). ANDA approval pathways and bioequivalence. U.S. Food and Drug Administration.